Cristiana Sessa, MD

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for

PARP inhibitors have been the big development in ovarian cancer, Sessa says. However, it would be beneficial to have other compounds which can interact within the same pathway and be combined with PARP inhibitors.

ATR inhibitors, for example, protect the genomic integrity of cells by blocking the cell cycle and giving them time to repair.  These compounds, which are in clinical development, can be combined with other drugs like PARP inhibitors, and can be used in tumor types which are particularly sensitive, like those that lack p53 or tumors that are ataxiatelangiectasia mutation (ATM)-deficient.

Videos

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for <em>BRCA</em>1/2-mutated tumors.&nbsp;

Cristiana Sessa, MD | Authors

Articles

Targeted Therapies for Patients With Ovarian Cancer Who Have BRCA-Mutated Tumors